Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients

Ahn, 2005, Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses, J. Pharmacokinet. Pharmacodyn., 32, 703, 10.1007/s10928-005-0083-6 Akbas, 2005, Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods, Clin. Biochem., 38, 552, 10.1016/j.clinbiochem.2005.02.011 Anderson, 2008, Mechanism-based concepts of size and maturity in pharmacokinetics, Annu. Rev. Pharmacol. Toxicol., 48, 303, 10.1146/annurev.pharmtox.48.113006.094708 Brunet, 2019, Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report, Ther. Drug Monit., 41, 261, 10.1097/FTD.0000000000000640 Campagne, 2019, Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?, J. Clin. Pharmacol., 59, 309, 10.1002/jcph.1325 Christians, 2002, Mechanisms of clinically relevant drug interactions associated with tacrolimus, Clin. Pharmacokinet., 41, 813, 10.2165/00003088-200241110-00003 Christie, 2010, The registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report–2010, J. Heart Lung Transplant., 29, 1104, 10.1016/j.healun.2010.08.004 Dirks, 2004, Pharmacokinetics of immunosuppressants: a perspective on ethnic differences, Int. J. Clin. Pharmacol. Ther., 42, 701, 10.5414/CPP42701 2016, EASL Clinical practice guidelines: liver transplantation, J. Hepatol., 64, 433, 10.1016/j.jhep.2015.10.006 Fu, 2019, Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation, Acta Pharmacol. Sin., 40, 151, 10.1038/s41401-018-0070-2 Fulop, 1985, Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects., Gerontology, 31, 6 Huang, 2020, Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: a comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model, Eur. J. Pharm. Sci., 143, 10.1016/j.ejps.2019.105199 Jacobson, 2011, Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium, Transplantation, 91, 300, 10.1097/TP.0b013e318200e991 Jacobson, 2012, Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs, Am. J. Transplant., 12, 3326, 10.1111/j.1600-6143.2012.04232.x Jusko, 1995, Pharmacokinetics of tacrolimus in liver transplant patients, Clin. Pharmacol. Ther., 57, 281, 10.1016/0009-9236(95)90153-1 Lee, 2016, Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system, Int. J. Nanomed., 11, 1109 Li, 2011, Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective, Pharmacogenomics J., 11, 300, 10.1038/tpj.2010.42 Mao, 2013, Initial experience of lung transplantation at a single center in China, Transplant. Proc., 45, 349, 10.1016/j.transproceed.2012.02.045 Miano, 2019, Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury, Clin. Pharmacol. Ther., 107, 462, 10.1002/cpt.1629 Moller, 1999, The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects, Drug Metab. Dispos., 27, 633 Monchaud, 2012, Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation, Clin. Pharmacokinet., 51, 175, 10.2165/11594760-000000000-00000 de la, 2010, Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment, Transplant. Proc., 42, 3217, 10.1016/j.transproceed.2010.05.064 Pou, 1998, Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients, Transpl. Int., 11, S270, 10.1111/j.1432-2277.1998.tb01131.x Saint-Marcoux, 2005, Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies, Clin. Pharmacokinet., 44, 1317, 10.2165/00003088-200544120-00010 Sikma, 2019, Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation, Clin. Pharmacokinet., 59, 771, 10.1007/s40262-019-00854-1 Staatz, 2010, Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I, Clin. Pharmacokinet., 49, 141, 10.2165/11317350-000000000-00000 Staatz, 2004, Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation, Clin. Pharmacokinet., 43, 623, 10.2165/00003088-200443100-00001 Staatz, 2011, Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?, Clin. Pharmacokinet., 50, 759, 10.2165/11596380-000000000-00000 Storset, 2014, Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling, Br. J. Clin. Pharmacol., 78, 509, 10.1111/bcp.12361 Tang, 2016, Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opin. Drug Metab. Toxicol., 12, 555, 10.1517/17425255.2016.1170808 Vanhove, 2016, Clinical determinants of calcineurin inhibitor disposition: a mechanistic review, Drug Metab. Rev., 48, 88, 10.3109/03602532.2016.1151037 Vanhove, 2016, Comparative performance of oral midazolam clearance and plasma 4beta-hydroxycholesterol to explain interindividual variability in tacrolimus clearance, Br. J. Clin. Pharmacol., 82, 1539, 10.1111/bcp.13083 Wade, 1993, Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis, J. Pharmacokinet. Biopharm., 21, 209, 10.1007/BF01059771 Wallinder, 2019, Outcomes and long-term survival after pulmonary retransplantation: a single-center experience, Ann. Thorac. Surg., 108, 1037, 10.1016/j.athoracsur.2019.04.028 Wang, 2019, Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models, Exp. Ther. Med., 17, 4023 Wang, 2009, CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation, Expert Rev. Mol. Diagn., 9, 383, 10.1586/erm.09.11 Wehbe, 2013, Recovery from AKI and short- and long-term outcomes after lung transplantation, Clin. J. Am. Soc. Nephrol., 8, 19, 10.2215/CJN.04800512 Yu, 2018, Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation, Curr. Drug Metab., 19, 513, 10.2174/1389200219666180129151948 Zhao, 2016, External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients, Br. J. Clin. Pharmacol., 81, 891, 10.1111/bcp.12830 Zheng, 2004, Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, J. Clin. Pharmacol., 44, 135, 10.1177/0091270003262108